Clinical Trial Update: Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial investigating crenezumab vs placebo in preclinical PSEN1 E280A mutation carriers with a tau PET longitudinal substudy; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Crenezumab

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-03-15